169: Systematic Review of Patient Reported Quality of Life Following Stereotactic Ablative Body Radiotherapy for Primary and Metastatic Liver Cancer  by Mutsaers, Adam et al.
S62                                                                                     CARO 2016 
_________________________________________________________________________________________________________ 
varied from 0 to 46.8% (median 4.2%) in the primary tumour. The 
Tmax/Mmean ranged from 1.37 to 4.23 (median 1.98). There was 
no correlation between lesion size and SUVmax or between lesion 
size and HF, which suggests that larger tumours are not 
necessarily more hypoxic than smaller tumours. A significant 
correlation between Tmax/Mmean and HF was observed (rho = 
0.83, p < 0.001), and between SUVmax and HF (rho = 0.74, p = 
0.004). This may suggest that tumours with a higher SUVmax (ie. 
higher intensity of hypoxia) also have a larger proportional 
volume of hypoxia.  
Conclusions: 18F-FAZA PET scans provide a feasible non-invasive 
method to assess NSCLC tumour hypoxia. A hypoxic volume, as 
detected by 18F-FAZA PET, was present in the majority of NSCLC 
patients in our study. Ongoing trial accrual and follow up of our 
patient cohort will provide more information with regards to the 
imaging and clinical value of 18F-FAZA PET, and we hope to 
correlate these imaging metrics with clinical outcomes. 
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Purpose: Radiotherapy (RT) practice variability in the palliative 
setting is well-documented. Clinical practice guidelines inform 
standardized, evidence-based, beneficial practice, while 
simultaneously discouraging unnecessary or potentially harmful 
practices. The process of creating provincial palliative RT clinical 
practice guidelines is associated with multiple challenges. We 
describe the unique approach required in aligning 
multidisciplinary goals as compared to traditional tumour site-
specific guidelines. 
Methods and Materials: Radiation oncologists from the 
provincial Palliative Care Tumour Team, along with guideline 
specialists from the Guideline Resource Unit, formed the primary 
guideline working group tasked with updating the Palliative RT 
guidelines. Tumour site specific representatives (ex. Central 
Nervous System Tumour Team) were incorporated as needed, as 
well as experts in supportive care, on a guideline by guideline 
basis. For each guideline, a systematic literature review was 
conducted to identify relevant evidence. Recommendations 
were initially developed within the primary working group, then 
revised in collaboration with experts from other disciplines. 
Once working group consensus was reached, guideline 
recommendations were circulated to all radiation oncologists 
and Palliative Tumour Team members for input. After several 
rounds of feedback and modifications, provincial consensus was 
reached. 
Results: Initially, one RT guideline had been created for all 
provincial palliative RT recommendations. These guidelines have 
since been split into smaller, more functional palliative RT 
guidelines: 1) Brain Metastases; 2) Bone Metastases and Spinal 
Cord Compression; 3) Bleeding and Gastrointestinal Obstruction; 
and 4) Superior Vena Cava Obstruction, Dyspnea, and 
Hemoptysis. The majority of recommendations were either 
modified or new due to advancements in research or changes in 
consensus based approaches. In total, 70 recommendations were 
approved. Recommendations were supported by a range of 
evidence from high (level one evidence) to low quality 
(consensus opinion). 
Conclusions: By combining the newly updated palliative RT 
guidelines with an educational intervention, variations in 
practice may be mitigated. Using our model, similar efforts can 
be undertaken in other jurisdictions. 
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Purpose: Stereotactic ablative body radiotherapy (SABR) is an 
emerging modality in patients with liver cancer who are 
ineligible for other local therapies. It has been shown to be 
effective with respect to long-term tumour control with minimal 
toxicity. However SABR for liver cancer is not current standard 
of practice despite its potential promise. In order to validate 
increased offering of this promising therapy, objective 
systematic data regarding impact on quality of life (QOL) is 
required. No systematic reviews to date have been performed to 
analyze QOL for primary or metastatic liver cancers. QOL metrics 
are a critical part of therapy evaluation, particularly in disease 
states with short life expectancy. The purpose of this study was 
to conduct a systematic review of evidence surrounding QOL for 
liver SABR.  
Methods and Materials: MEDLINE and EMBASE databases from 
1996 to October 2015 were queried to obtain English language 
studies analysing QOL following SABR for liver cancers. Included 
studies involved patient-reported QOL as either a primary or 
secondary endpoint, along with analysis of QOL change over 
time. Studies were screened by three reviewers, while relevant 
data were abstracted and analyzed by a single reviewer.  
Results: Of 2181 initially screened studies, five met all inclusion 
criteria and were analyzed. Extracted study dates ranged from 
2008 to 2015, included a total of 388 eligible patients, and 4/5 
studies were prospective in design. All were published studies, 
with the exception of one conference abstract. Studies included 
patients with hepatocellular carcinoma, liver metastases and 
intrahepatic cholangiocarcinoma. Extracted studies were 
heterogeneous in dose prescription used (11-70 Gy in 3 – 30 
fractions), as well as in QOL metrics (EORTC QLQ C-15 PAL,/C-
30/LM-21, Euroqol 5D, FACT-Hep, FLIC) and final endpoints 
(range: six weeks to 12 months). Despite this there were few 
clinically or statistically significant declines in QOL scores 
following SABR. Four studies demonstrated increased fatigue 
transiently in the first 1-4 weeks, while two studies showed 
transient worsening of appetite at one month; both metrics 
returned to insignificant difference from baseline by the final 
endpoints. All studies showed no significant decline in QOL at 
their respective endpoints. In studies with overlapping QOL 
tools, estimates of three-month post-SABR global QOL were 
similar. 
Conclusions: Results of this systematic review demonstrate well-
preserved post SABR QOL in patients with otherwise untreatable 
liver cancer, despite heterogeneity amongst the individual 
studies themselves. These findings merit further research to 
increase data collection, to validate QOL tools specific to SABR 
for liver cancers, and to support comparative effectiveness trials 
of SABR with other local modalities in liver cancer including 
surgery, chemoembolization and radiofrequency ablation, with a 
focus on QOL outcomes as an important endpoint. 
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